ArticleMolecular cancer2022
Two circPPFIA1s negatively regulate liver metastasis of colon cancer via miR-155-5p/CDX1 and HuR/RAB36.
Article in Molecular cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bibliometric and visual analysis of global crc circular RNA research 2015-2023.Frontiers in immunology · 2025Pooled it
- The Impact of the FXR1-FUBP1 Axis on Chemotherapy Resistance in LUSC Cells.Biochemical genetics · 2026Article
- The Oncogenic Role of Prostate Stem Cell Antigen (PSCA) in Colorectal Cancer: Implications for Targeted Therapy.Current issues in molecular biology · 2026Article
- Identification and validation of a Golgi apparatus related gene signature for prognosis prediction and immune microenvironment profiling in colorectal cancer.Discover oncology · 2026Article
- Hsa_circ_0007158 promotes colorectal cancer progression via the ceRNA axis and its association with immune infiltration.Cancer cell international · 2026Article
- miR-155-5p promotes osteosarcoma progression and cisplatin resistance by targeting the SOCS1/STAT1/c-Fos signaling axis.Discover oncology · 2026Article
- Potential role ofBiochemistry and biophysics reports · 2026Article
- Hsa_circ_0002103 promotes progression of colorectal cancer via miR-193a-3p/CCND1 axis.Molecular and cellular biochemistry · 2026Article
- Noncoding RNAs: A Novel Frontier in Liver Cancer Research and Therapy: Implications for Precision Oncology.Sub-cellular biochemistry · 2026Review
- Circular RNA circMYBL2 regulates the progression of ovarian cancer through miR-195-5P/BIRC5 axis.Journal of ovarian research · 2025Article
- MiR-142-3p targets the CXCL12/WNT/β-catenin pathway to regulate the stemness of breast cancer cells.Scientific reports · 2025Article
- Unraveling the miR-144-3p/PUMA pathway: a novel regulator of FDX1-mediated cuproptosis in colorectal cancer.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- Cardiomyocyte lncRNA Cpat maintains cardiac homeostasis and mitochondria function by targeting citrate synthase acetylation.Nature communications · 2025Article
- Circular RNAs and mammalian follicular development: current insights and future prospects-an updated review.Cell death discovery · 2025Review
- MiR-203a-3p in extracellular vesicles derived from mesenchymal stem cells alleviates BPD-associated apoptosis and inflammation.Stem cell research & therapy · 2025Article
- Mitochondrial metabolic reprogramming in colorectal cancer: mechanisms of resistance and future clinical interventions.Cell death discovery · 2025Review
- The LncRNA GABARAPL3/miR-155-5p axis modulates the proliferation and invasion of liver cancer cells by regulating GABARAPL1.Molecular biology reports · 2025Article
- CDX1 improves nicotine induced cardiac fibroblasts activation and cardiomyocyte hypertrophy by alleviating autophagic flux impairment through modulation of LAPTM4B.Scientific reports · 2025Article
- The miR-155-5p/Translational cancer research · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCircular RNAs (circRNAs) play a critical role in colorectal cancer (CRC) progression, including metastasis. However, the detailed molecular mechanism is not fully understood.
methodsDifferentially expressed circRNAs between primary KM12C and liver metastatic KM12L4 colon cancer cells were identified by microarray. The expression of circRNAs was measured by semi-quantitative (semi-qPCR) and real time-quantitative PCR (RT-qPCR). Metastatic potential including invasive and migratory abilities, and liver metastasis were examined by transwell assays and intrasplenic injection, respectively. CircPPFIA1-associated microRNA (miRNA) and RNA-binding protein (RBP) were screened by an antisense oligonucleotide (ASO) pulldown experiment. The effects of circPPFIA1 on target gene expression were evaluated by RT-qPCR and western blot analyses.
resultsBy analyzing circRNA microarray data, we identified two anti-metastatic circRNAs generated from PPFIA1 with different length, which named circPPFIA1-L (long) and -S (short). They were significantly downregulated in liver metastatic KM12L4 cells compared to primary KM12C cells. The knockdown of circPPFIA1s in KM12C enhanced metastatic potential and increased liver metastasis. Conversely, overexpression of circPPFIA1s weakened metastatic potential and inhibited liver metastasis. circPPFIA1s were found to function as sponges of oncogenic miR-155-5p and Hu antigen R (HuR) by an ASO pulldown experiment. circPPFIA1s upregulated tumor-suppressing CDX1 expression and conversely downregulated oncogenic RAB36 by decoying miR-155-5p and by sequestering HuR, respectively.
conclusionOur findings demonstrate that circPPFIA1s inhibit the liver metastasis of CRC via the miR-155-5p/CDX1 and HuR/RAB36 pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.